— Know what they know.
Not Investment Advice
Also trades as: MXCT.L (LSE) · $vol 0M

MXCT NASDAQ

MaxCyte, Inc.
1W: -2.8% 1M: +19.1% 3M: +43.4% YTD: -31.6% 1Y: -51.4% 3Y: -71.3%
$1.04
-0.02 (-1.89%)
 
Weekly Expected Move ±14.3%
$1 $1 $1 $1 $1
NASDAQ · Healthcare · Medical - Devices · Alpha Radar Strong Buy · Power 64 · $111.4M mcap · 99M float · 0.996% daily turnover · Short 14% of daily vol

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue
$33M -14.5% ▼
5Y CAGR: +4.8%
Gross Profit
$23M -28.4% ▼
5Y CAGR: -0.7%
Operating Income
-$44M +14.9% ▲
Net Income
-$45M -8.7% ▼
EPS (Diluted)
$-0.42 -7.7% ▼
EBITDA
-$38M +17.2% ▲

Profit Margins

Year-over-Year Growth

View Full Income Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
Revenue$34M$44M$41M$39M$33M
YoY Growth+29.5%+30.6%-6.7%-6.4%-14.5%
Cost of Revenue$4M$5M$5M$7M$10M
Gross Profit$30M$39M$37M$32M$23M
Gross Margin89.2%88.5%88.5%81.6%68.4%
R&D Expenses$15M$20M$24M$22M$21M
SG&A Expenses$32M$44M$57M$56M$47M
Operating Expenses$48M$67M$85M$83M$72M
Operating Income-$18M-$27M-$48M-$51M-$44M
Operating Margin-53.7%-61.8%-117.0%-132.5%-131.9%
Interest Expense$1M$127K$0$0$0
Income Before Tax-$19M-$24M-$38M-$41M-$45M
Tax Expense$0$0$0$0$0
Net Income-$19M-$24M-$38M-$41M-$45M
Net Margin-56.3%-53.3%-91.8%-106.3%-135.1%
EPS (Diluted)$-0.22$-0.19$-0.37$-0.39$-0.42
EBITDA-$17M-$25M-$44M-$46M-$38M
Shares Outstanding91M102M103M105M106M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms